Workflow
自主可控芯片研发
icon
Search documents
114.28元 摩尔线程发行价确定!战配名单出炉
来源:中国证券报 从网下询价情况看,摩尔线程公告称,剔除无效报价后,284家网下投资者管理的7766个配售对象全部 符合《发行安排及初步询价公告》规定的网下投资者的条件,报价区间为88.79元/股至159.57元/股,拟 申购数量总和为728.99亿股。 公告显示,剔除无效报价、最高报价以及低于发行价的报价,本次网下发行提交有效报价的网下投资者 数量为267家,管理的配售对象数量为7555个,对应的有效拟申购数量总和为704.06亿股,对应的有效 申购倍数为战略配售回拨前网下初始发行规模的1571.56倍。 战配名单出炉 备受央企、地方国资青睐 11月20日,摩尔线程发布首次公开发行股票并在科创板上市发行公告,本次公开发行日期为11月24日, 发行价格为114.28元/股,对应的2024年摊薄后静态市销率为122.51倍,高于同行业可比公司2024年静态 市销率平均水平。 公告称,按此发行价预估,摩尔线程上市时市值约为537.15亿元。 网下有效申购倍数超1500倍 摩尔线程自2020年成立以来,始终专注于全功能GPU的自主研发与设计。 摩尔线程目前尚未盈利,公告称,如公司上市时仍未盈利,将自上市之日起纳入科 ...
摩尔线程冲击科创板年内最大IPO:募资80亿元、无控股股东
Sou Hu Cai Jing· 2025-07-01 09:27
Core Viewpoint - Moores Threads has been accepted for IPO on the Sci-Tech Innovation Board, aiming to raise approximately 8 billion yuan, marking it as the largest IPO accepted this year on the board and the second largest across the Shanghai, Shenzhen, and Beijing exchanges [2]. Group 1: Company Overview - Moores Threads was established in October 2020 with a registered capital of 330 million yuan, focusing on providing AI computing support for digital transformation across various industries [2]. - The company specializes in full-function GPUs and aims to offer accelerated computing infrastructure and one-stop solutions globally [2]. Group 2: Fundraising and Investment Plans - The company plans to invest the raised funds into several key projects, including the development of next-generation autonomous AI training integrated chips, graphics chips, and AI SoC chips, along with supplementing working capital [4][6]. - The total amount of funds intended for investment in these projects is approximately 800 million yuan [3][4]. Group 3: Financial Performance - The company reported revenues of approximately 46.09 million yuan, 124.00 million yuan, and 438.46 million yuan for the years 2022, 2023, and 2024, respectively [7]. - Corresponding net losses were approximately 184 million yuan, 167.33 million yuan, and 149.19 million yuan for the same years, indicating a trend of reduced losses over the reporting period [7]. - The research and development expense ratios were exceptionally high at 2422.51%, 1076.31%, and 309.88% for the years 2022, 2023, and 2024, respectively [7].